<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082833</url>
  </required_header>
  <id_info>
    <org_study_id>2016-08-016</org_study_id>
    <nct_id>NCT03082833</nct_id>
  </id_info>
  <brief_title>Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy</brief_title>
  <official_title>Samsung Medical Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial of AZD2014 in TSC1/2 mutated or TSC1/2 null GC patients as second-line&#xD;
      chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZD2014 50mg BD continuous schedule of a 28 day cycle AZD2014 will be administered with&#xD;
      orange juice in STG/TG patients. AZD2014 can be taken with or without food. The first dose of&#xD;
      the day should be taken at approximately the same time each morning.The second dose of the&#xD;
      day should be taken approximately 12 hours after the morning dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">November 16, 2018</completion_date>
  <primary_completion_date type="Actual">November 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) by RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate (ORR) by RECIST 1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cancer of Stomach</condition>
  <arm_group>
    <arm_group_label>AZD2014 50mg BD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2014 50mg BD continuous schedule of a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2014</intervention_name>
    <description>AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).</description>
    <arm_group_label>AZD2014 50mg BD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of fully informed consent prior to any study specific procedures.&#xD;
&#xD;
          2. Patients must be ≥20 years of age.&#xD;
&#xD;
          3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after&#xD;
             first-line therapy.&#xD;
&#xD;
               -  The 1st line regimen must have contained doublet 5-fluoropyrimidine and platinum&#xD;
                  based regimen.&#xD;
&#xD;
               -  Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy&#xD;
                  containing doublet 5-fluoropyrimidine and platinum-based regimen could be&#xD;
                  considered as 1st line therapy.&#xD;
&#xD;
               -  Acceptable prior chemotherapy regimens for this protocol are chemotherapy&#xD;
                  regimens that include Immune Target agent therapy. (such as a pembrolizumab,&#xD;
                  ramucirumab etc)&#xD;
&#xD;
          4. Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months&#xD;
             prior to starting the 1st line therapy.&#xD;
&#xD;
          5. Provision of tumor sample (from eith tumor sample (from eith tumor sample (from eith&#xD;
             tumor sample (from eith tumor sample (from eith er a resection or biopsy)er a&#xD;
             resection or biopsy) er a resection or biopsy)er a resection or biopsy) er a resection&#xD;
             or biopsy)er a resection or biopsy)er a resection or biopsy)er a resection or&#xD;
             biopsy)er a resection or biopsy) er a resection or biopsy) er a resection or biopsy)&#xD;
             er a resection or biopsy)er a resection or biopsy)&#xD;
&#xD;
          6. Patients with TSC1/2 mutation or null through the VIKTORY trial. (The VIKTORY trial&#xD;
             uses Ion Torrent PGM to screen for a panel of cancer mutations and nanostring copy&#xD;
             number variation panel (see addendum for the VIKTORY trial). Types of TSC1/2 mutation&#xD;
             for this trial was defined in VIKTORY lab manual&#xD;
&#xD;
          7. Patients are willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits and examinations.&#xD;
&#xD;
          8. ECOG performance status 0-2.&#xD;
&#xD;
          9. Patients must have a life expectancy ≥ 3 months from proposed first dose date.&#xD;
&#xD;
         10. Patients must have acceptable bone marrow, liver and renal function measured within 28&#xD;
             days prior to administration of study treatment as defined below:&#xD;
&#xD;
             - Haemoglobin ≥9.0 g/dL (transfusion allowed)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  White blood cells (WBC) &gt; 3 x 109/L&#xD;
&#xD;
               -  Platelet count ≥100 x 109/L (transfusion allowed)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver&#xD;
                  metastases are present in which case it must be ≤ 5x ULN&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x institutional ULN&#xD;
&#xD;
         11. At least one measurable lesion that can be accurately assessed by imaging or physical&#xD;
             examination at baseline and following up visits.&#xD;
&#xD;
         12. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed&#xD;
             prior to treatment on day 1. Patients of child-bearing potential should be using&#xD;
             adequate contraceptive measures (two forms of highly reliable methods) should not be&#xD;
             breast feeding and must have a negative pregnancy test prior to start of dosing.Or&#xD;
             Patients must have evidence of non-child-bearing potential by fulfilling one of the&#xD;
             following criteria at screening: Post-menopausal - defined as aged more than 50 years&#xD;
             and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal&#xD;
             treatments. Documentation of irreversible surgical sterilisation by hysterectomy,&#xD;
             bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant&#xD;
             chemotherapy with more than 6 month wash out period) for the treatment of gastric&#xD;
             cancer in the advanced setting.&#xD;
&#xD;
             2. Any previous treatment with PIK3CA, AKT or mTOR inhibitor or agents with mixed PI3K&#xD;
             / mTOR activity.&#xD;
&#xD;
             3. Patients with second primary cancer, except: adequately treated non-melanoma skin&#xD;
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours&#xD;
             curatively treated with no evidence of disease for ≤5 years.&#xD;
&#xD;
             4. Patients unable to swallow orally administered medication. 5. Previous major&#xD;
             surgery within 4 weeks prior to enrollment. 6. For AZD2014: Exposure to potent or&#xD;
             moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout periods&#xD;
             before the first dose of study treatment 8. With the exception of alopecia, any&#xD;
             ongoing toxicities (&gt;CTCAE grade 1) caused by previous cancer therapy.&#xD;
&#xD;
             9. Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks&#xD;
             before the enrollment.&#xD;
&#xD;
             10. Resting ECG with measurable QTcB &gt; 450 msec on 2 or more time points within a 24&#xD;
             hour period or family history of long QT syndrome.&#xD;
&#xD;
             11. Patients with cardiac problem as follows: uncontrolled hypertension (BP ≥150/95&#xD;
             mmHg despite medical therapy) Left ventricular ejection fraction &lt;55% measured by&#xD;
             echocardiography, Atrial fibrillation with a ventricular rate &gt;100 bpm on ECG at rest&#xD;
             , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy,&#xD;
             Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society&#xD;
             grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to&#xD;
             starting treatment 12. Active or untreated brain metastases or spinal cord compression&#xD;
             Patients with treated brain metastases or spinal cord compression are eligible if they&#xD;
             have minimal neurologic symptoms, evidence of stable disease (for at least 1 month) or&#xD;
             response on follow-up scan, and require no corticosteroid therapy for ≥ 1 week.&#xD;
&#xD;
             13. Female patients who are breast-feeding or child-bearing 14. Any evidence of severe&#xD;
             or uncontrolled systemic disease, active infection, active bleeding diatheses or renal&#xD;
             transplant, including any patient known to have hepatitis B, hepatitis C or human&#xD;
             immunodeficiency virus (HIV) 15. Patients with proteinuria (3+ on dipstick analysis )&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

